Shared on10 Oct 25Fair value Increased 3.95%
Kiniksa Pharmaceuticals' analyst price target has increased from $47 to about $48.86. Analysts cite continued commercial momentum, expanding product opportunities, and a positive earnings outlook as drivers of the higher valuation.
Shared on26 Sep 25Fair value Increased 1.08%
Kiniksa Pharmaceuticals International’s consensus price target was modestly raised to $47.00 on the back of strong commercial execution, robust launch momentum, and continued outperformance, reflecting optimism on deeper penetration and expansion opportunities. Analyst Commentary Strong commercial execution driving revenue outperformance.
Shared on01 Aug 25Fair value Increased 14%
Driven by an improvement in net profit margin and a lower future P/E multiple, Kiniksa Pharmaceuticals International’s fair value has been revised upward, with the consensus analyst price target rising from $40.83 to $45.17. What's in the News Raised 2025 net product revenue guidance to $625–$640 million from prior $590–$605 million.